S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: A microdialysis study

Disulfiram (DSF), used for the treatment of alcohol use disorders (AUDs) for over six decades, most recently has shown promise for treating cocaine dependence. Although DSF's mechanism of action in alcohol abuse is due to the inhibition of liver mitochondrial aldehyde dehydrogenase (ALDH2), its...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuropharmacology 2013-12, Vol.75, p.95-105
Hauptverfasser: Faiman, Morris D., Kaul, Swetha, Latif, Shaheen A., Williams, Todd D., Lunte, Craig E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 105
container_issue
container_start_page 95
container_title Neuropharmacology
container_volume 75
creator Faiman, Morris D.
Kaul, Swetha
Latif, Shaheen A.
Williams, Todd D.
Lunte, Craig E.
description Disulfiram (DSF), used for the treatment of alcohol use disorders (AUDs) for over six decades, most recently has shown promise for treating cocaine dependence. Although DSF's mechanism of action in alcohol abuse is due to the inhibition of liver mitochondrial aldehyde dehydrogenase (ALDH2), its mechanism of action in the treatment of cocaine dependence is unknown. DSF is a pro-drug, forming a number of metabolites each with discrete pharmacological actions. One metabolite formed during DSF bioactivation is S-(N, N-diethylcarbamoyl) glutathione (carbamathione) (carb). We previously showed that carb affects glutamate binding. In the present studies, we employed microdialysis techniques to investigate the effect of carb administration on dopamine (DA), GABA, and glutamate (Glu) in the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), two brain regions implicated in substance abuse dependence. The effect of DSF on DA, GABA, and Glu in the NAc also was determined. Both studies were carried out in male rats. Carb (20, 50, 200 mg/kg i v) in a dose-dependent manner increased DA, decreased GABA, and had a biphasic effect on Glu, first increasing and then decreasing Glu in both the NAc and mPFC. These changes all occurred concurrently. After carb administration, NAc and mPFC carb, as well as carb in plasma, were rapidly eliminated with a half-life for each approximately 4 min, while the changes in DA, GABA, and GLu in the NAc and mPFC persisted for approximately two hours. The maximal increase in carb (Cmax) in the NAc and mPFC after carb administration was dose-dependent, as was the area under the curve (AUC). DSF (200 mg/kg i p) also increased DA, decreased GABA, and had a biphasic effect on Glu in the NAc similar to that observed in the NAc after carb administration. When the cytochrome P450 inhibitor N-benzylimidazole (NBI) (20 mg/kg i p) was administered before DSF dosing, no carb could be detected in the NAc and plasma and also no changes in NAc DA, GABA, and GLu occurred. Changes in these neurotransmitters occurred only if carb was formed from DSF. When NBI was administered prior to dosing with carb, the increase in DA, decrease in GABA, and biphasic effect on GLu was similar to that seen after dosing with carb only. The i p or i v administration of carb showed similar changes in DA, GABA, and GLu, except the time to reach Cmax for DA as well as the changes in GABA, and GLu after i p administration occurred later. The elimination half-life of carb
doi_str_mv 10.1016/j.neuropharm.2013.07.007
format Article
fullrecord <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4631046</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0028390813003249</els_id><sourcerecordid>S0028390813003249</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-76190fdc8b1f750d422436440974652a4cf427be6b7e2538baa3eb192aa793353</originalsourceid><addsrcrecordid>eNqFkcFuEzEQhi0EoiHwCsjHVsoGe-2sdzkgpRVtkapyAM7WrD3bONq1I9tbNe_Gw7FNSoETF1se___8Hn-EUM6WnPHqw3bpcYxht4E4LEvGxZKpJWPqBZnxWolCsUq-JDPGyroQDatPyJuUtowxWfP6NTkpRd3wmlcz8vNbcXq7oLeFdZg3-95AbGEI-_7srh8z5I0LHunpsfx0PFtQoNalse9chIEOmKENvctIwVvqcqLYdWgyDZ760fQ4JgrGjEOLPh00u4hdDD5DT02IGR-oDTsYnMcFvVqfrxcH1eEJUyp-pGs6OBODddDvk0s05dHu35JXHfQJ3z3tc_Lj8vP3i-vi5uvVl4v1TWGkanKhKt6wzpq65Z1aMSvLUopKStYoWa1KkKaTpWqxahWWK1G3AAJb3pQAqhFiJebk07HvbmwHtAZ9jtDrXXQDxL0O4PS_N95t9F2417ISnE3LnNTHBtMIKU2zP3s5049E9Vb_IaofiWqm9ER0sr7_O_vZ-BvhJDg_CnD6gXuHUSfj0Bu0Lk4MtA3u_ym_AO7kvGk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: A microdialysis study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Faiman, Morris D. ; Kaul, Swetha ; Latif, Shaheen A. ; Williams, Todd D. ; Lunte, Craig E.</creator><creatorcontrib>Faiman, Morris D. ; Kaul, Swetha ; Latif, Shaheen A. ; Williams, Todd D. ; Lunte, Craig E.</creatorcontrib><description>Disulfiram (DSF), used for the treatment of alcohol use disorders (AUDs) for over six decades, most recently has shown promise for treating cocaine dependence. Although DSF's mechanism of action in alcohol abuse is due to the inhibition of liver mitochondrial aldehyde dehydrogenase (ALDH2), its mechanism of action in the treatment of cocaine dependence is unknown. DSF is a pro-drug, forming a number of metabolites each with discrete pharmacological actions. One metabolite formed during DSF bioactivation is S-(N, N-diethylcarbamoyl) glutathione (carbamathione) (carb). We previously showed that carb affects glutamate binding. In the present studies, we employed microdialysis techniques to investigate the effect of carb administration on dopamine (DA), GABA, and glutamate (Glu) in the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), two brain regions implicated in substance abuse dependence. The effect of DSF on DA, GABA, and Glu in the NAc also was determined. Both studies were carried out in male rats. Carb (20, 50, 200 mg/kg i v) in a dose-dependent manner increased DA, decreased GABA, and had a biphasic effect on Glu, first increasing and then decreasing Glu in both the NAc and mPFC. These changes all occurred concurrently. After carb administration, NAc and mPFC carb, as well as carb in plasma, were rapidly eliminated with a half-life for each approximately 4 min, while the changes in DA, GABA, and GLu in the NAc and mPFC persisted for approximately two hours. The maximal increase in carb (Cmax) in the NAc and mPFC after carb administration was dose-dependent, as was the area under the curve (AUC). DSF (200 mg/kg i p) also increased DA, decreased GABA, and had a biphasic effect on Glu in the NAc similar to that observed in the NAc after carb administration. When the cytochrome P450 inhibitor N-benzylimidazole (NBI) (20 mg/kg i p) was administered before DSF dosing, no carb could be detected in the NAc and plasma and also no changes in NAc DA, GABA, and GLu occurred. Changes in these neurotransmitters occurred only if carb was formed from DSF. When NBI was administered prior to dosing with carb, the increase in DA, decrease in GABA, and biphasic effect on GLu was similar to that seen after dosing with carb only. The i p or i v administration of carb showed similar changes in DA, GABA, and GLu, except the time to reach Cmax for DA as well as the changes in GABA, and GLu after i p administration occurred later. The elimination half-life of carb and the area under the curve (AUC) were similar after both routes of administration. It is concluded that carb must be formed from DSF before any changes in DA, GABA, and GLu in the NAc and mPFC are observed. DSF and carb, when administered to rats, co-release DA, GABA, and GLu. Carb, once formed can cross the blood brain barrier and enter the brain. Although inhibition of liver ALDH2 is the accepted mechanism for DSF's action in treating AUDs, the concurrent changes in DA, GABA, and GLu in the NAc and mPFC after DSF administration suggest that changes in these neurotransmitters as a potential mechanism of action not only for AUDs, but also for cocaine dependence cannot be excluded. •Microdialysis study shows disulfiram effects on dopamine, GABA, and glutamate.•Disulfiram in NAC and mPFC increases dopamine, decreases GABA, and has biphasic effect on glutamate.•Disulfiram effect due to metabolite carbamathione.•If no carbamathione formed from disulfiram, no change in neurotransmitters occur.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/j.neuropharm.2013.07.007</identifier><identifier>PMID: 23891816</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adrenergic alpha-Antagonists - pharmacology ; Analysis of Variance ; Animals ; Carbamathione ; Disulfiram ; Dopamine ; Dopamine - metabolism ; Dose-Response Relationship, Drug ; GABA ; gamma-Aminobutyric Acid - metabolism ; Glutamate ; Glutamic Acid - metabolism ; Glutathione - analogs &amp; derivatives ; Glutathione - chemistry ; Glutathione - metabolism ; Glutathione - pharmacology ; Imidazoles - pharmacology ; Male ; Microdialysis ; Nucleus Accumbens - drug effects ; Nucleus Accumbens - metabolism ; Prefrontal Cortex - drug effects ; Prefrontal Cortex - metabolism ; Rats ; Rats, Sprague-Dawley ; Time Factors</subject><ispartof>Neuropharmacology, 2013-12, Vol.75, p.95-105</ispartof><rights>2013 Elsevier Ltd</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-76190fdc8b1f750d422436440974652a4cf427be6b7e2538baa3eb192aa793353</citedby><cites>FETCH-LOGICAL-c479t-76190fdc8b1f750d422436440974652a4cf427be6b7e2538baa3eb192aa793353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neuropharm.2013.07.007$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23891816$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Faiman, Morris D.</creatorcontrib><creatorcontrib>Kaul, Swetha</creatorcontrib><creatorcontrib>Latif, Shaheen A.</creatorcontrib><creatorcontrib>Williams, Todd D.</creatorcontrib><creatorcontrib>Lunte, Craig E.</creatorcontrib><title>S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: A microdialysis study</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>Disulfiram (DSF), used for the treatment of alcohol use disorders (AUDs) for over six decades, most recently has shown promise for treating cocaine dependence. Although DSF's mechanism of action in alcohol abuse is due to the inhibition of liver mitochondrial aldehyde dehydrogenase (ALDH2), its mechanism of action in the treatment of cocaine dependence is unknown. DSF is a pro-drug, forming a number of metabolites each with discrete pharmacological actions. One metabolite formed during DSF bioactivation is S-(N, N-diethylcarbamoyl) glutathione (carbamathione) (carb). We previously showed that carb affects glutamate binding. In the present studies, we employed microdialysis techniques to investigate the effect of carb administration on dopamine (DA), GABA, and glutamate (Glu) in the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), two brain regions implicated in substance abuse dependence. The effect of DSF on DA, GABA, and Glu in the NAc also was determined. Both studies were carried out in male rats. Carb (20, 50, 200 mg/kg i v) in a dose-dependent manner increased DA, decreased GABA, and had a biphasic effect on Glu, first increasing and then decreasing Glu in both the NAc and mPFC. These changes all occurred concurrently. After carb administration, NAc and mPFC carb, as well as carb in plasma, were rapidly eliminated with a half-life for each approximately 4 min, while the changes in DA, GABA, and GLu in the NAc and mPFC persisted for approximately two hours. The maximal increase in carb (Cmax) in the NAc and mPFC after carb administration was dose-dependent, as was the area under the curve (AUC). DSF (200 mg/kg i p) also increased DA, decreased GABA, and had a biphasic effect on Glu in the NAc similar to that observed in the NAc after carb administration. When the cytochrome P450 inhibitor N-benzylimidazole (NBI) (20 mg/kg i p) was administered before DSF dosing, no carb could be detected in the NAc and plasma and also no changes in NAc DA, GABA, and GLu occurred. Changes in these neurotransmitters occurred only if carb was formed from DSF. When NBI was administered prior to dosing with carb, the increase in DA, decrease in GABA, and biphasic effect on GLu was similar to that seen after dosing with carb only. The i p or i v administration of carb showed similar changes in DA, GABA, and GLu, except the time to reach Cmax for DA as well as the changes in GABA, and GLu after i p administration occurred later. The elimination half-life of carb and the area under the curve (AUC) were similar after both routes of administration. It is concluded that carb must be formed from DSF before any changes in DA, GABA, and GLu in the NAc and mPFC are observed. DSF and carb, when administered to rats, co-release DA, GABA, and GLu. Carb, once formed can cross the blood brain barrier and enter the brain. Although inhibition of liver ALDH2 is the accepted mechanism for DSF's action in treating AUDs, the concurrent changes in DA, GABA, and GLu in the NAc and mPFC after DSF administration suggest that changes in these neurotransmitters as a potential mechanism of action not only for AUDs, but also for cocaine dependence cannot be excluded. •Microdialysis study shows disulfiram effects on dopamine, GABA, and glutamate.•Disulfiram in NAC and mPFC increases dopamine, decreases GABA, and has biphasic effect on glutamate.•Disulfiram effect due to metabolite carbamathione.•If no carbamathione formed from disulfiram, no change in neurotransmitters occur.</description><subject>Adrenergic alpha-Antagonists - pharmacology</subject><subject>Analysis of Variance</subject><subject>Animals</subject><subject>Carbamathione</subject><subject>Disulfiram</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Dose-Response Relationship, Drug</subject><subject>GABA</subject><subject>gamma-Aminobutyric Acid - metabolism</subject><subject>Glutamate</subject><subject>Glutamic Acid - metabolism</subject><subject>Glutathione - analogs &amp; derivatives</subject><subject>Glutathione - chemistry</subject><subject>Glutathione - metabolism</subject><subject>Glutathione - pharmacology</subject><subject>Imidazoles - pharmacology</subject><subject>Male</subject><subject>Microdialysis</subject><subject>Nucleus Accumbens - drug effects</subject><subject>Nucleus Accumbens - metabolism</subject><subject>Prefrontal Cortex - drug effects</subject><subject>Prefrontal Cortex - metabolism</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Time Factors</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFuEzEQhi0EoiHwCsjHVsoGe-2sdzkgpRVtkapyAM7WrD3bONq1I9tbNe_Gw7FNSoETF1se___8Hn-EUM6WnPHqw3bpcYxht4E4LEvGxZKpJWPqBZnxWolCsUq-JDPGyroQDatPyJuUtowxWfP6NTkpRd3wmlcz8vNbcXq7oLeFdZg3-95AbGEI-_7srh8z5I0LHunpsfx0PFtQoNalse9chIEOmKENvctIwVvqcqLYdWgyDZ760fQ4JgrGjEOLPh00u4hdDD5DT02IGR-oDTsYnMcFvVqfrxcH1eEJUyp-pGs6OBODddDvk0s05dHu35JXHfQJ3z3tc_Lj8vP3i-vi5uvVl4v1TWGkanKhKt6wzpq65Z1aMSvLUopKStYoWa1KkKaTpWqxahWWK1G3AAJb3pQAqhFiJebk07HvbmwHtAZ9jtDrXXQDxL0O4PS_N95t9F2417ISnE3LnNTHBtMIKU2zP3s5049E9Vb_IaofiWqm9ER0sr7_O_vZ-BvhJDg_CnD6gXuHUSfj0Bu0Lk4MtA3u_ym_AO7kvGk</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Faiman, Morris D.</creator><creator>Kaul, Swetha</creator><creator>Latif, Shaheen A.</creator><creator>Williams, Todd D.</creator><creator>Lunte, Craig E.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20131201</creationdate><title>S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: A microdialysis study</title><author>Faiman, Morris D. ; Kaul, Swetha ; Latif, Shaheen A. ; Williams, Todd D. ; Lunte, Craig E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-76190fdc8b1f750d422436440974652a4cf427be6b7e2538baa3eb192aa793353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adrenergic alpha-Antagonists - pharmacology</topic><topic>Analysis of Variance</topic><topic>Animals</topic><topic>Carbamathione</topic><topic>Disulfiram</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Dose-Response Relationship, Drug</topic><topic>GABA</topic><topic>gamma-Aminobutyric Acid - metabolism</topic><topic>Glutamate</topic><topic>Glutamic Acid - metabolism</topic><topic>Glutathione - analogs &amp; derivatives</topic><topic>Glutathione - chemistry</topic><topic>Glutathione - metabolism</topic><topic>Glutathione - pharmacology</topic><topic>Imidazoles - pharmacology</topic><topic>Male</topic><topic>Microdialysis</topic><topic>Nucleus Accumbens - drug effects</topic><topic>Nucleus Accumbens - metabolism</topic><topic>Prefrontal Cortex - drug effects</topic><topic>Prefrontal Cortex - metabolism</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Faiman, Morris D.</creatorcontrib><creatorcontrib>Kaul, Swetha</creatorcontrib><creatorcontrib>Latif, Shaheen A.</creatorcontrib><creatorcontrib>Williams, Todd D.</creatorcontrib><creatorcontrib>Lunte, Craig E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Faiman, Morris D.</au><au>Kaul, Swetha</au><au>Latif, Shaheen A.</au><au>Williams, Todd D.</au><au>Lunte, Craig E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: A microdialysis study</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>75</volume><spage>95</spage><epage>105</epage><pages>95-105</pages><issn>0028-3908</issn><eissn>1873-7064</eissn><abstract>Disulfiram (DSF), used for the treatment of alcohol use disorders (AUDs) for over six decades, most recently has shown promise for treating cocaine dependence. Although DSF's mechanism of action in alcohol abuse is due to the inhibition of liver mitochondrial aldehyde dehydrogenase (ALDH2), its mechanism of action in the treatment of cocaine dependence is unknown. DSF is a pro-drug, forming a number of metabolites each with discrete pharmacological actions. One metabolite formed during DSF bioactivation is S-(N, N-diethylcarbamoyl) glutathione (carbamathione) (carb). We previously showed that carb affects glutamate binding. In the present studies, we employed microdialysis techniques to investigate the effect of carb administration on dopamine (DA), GABA, and glutamate (Glu) in the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), two brain regions implicated in substance abuse dependence. The effect of DSF on DA, GABA, and Glu in the NAc also was determined. Both studies were carried out in male rats. Carb (20, 50, 200 mg/kg i v) in a dose-dependent manner increased DA, decreased GABA, and had a biphasic effect on Glu, first increasing and then decreasing Glu in both the NAc and mPFC. These changes all occurred concurrently. After carb administration, NAc and mPFC carb, as well as carb in plasma, were rapidly eliminated with a half-life for each approximately 4 min, while the changes in DA, GABA, and GLu in the NAc and mPFC persisted for approximately two hours. The maximal increase in carb (Cmax) in the NAc and mPFC after carb administration was dose-dependent, as was the area under the curve (AUC). DSF (200 mg/kg i p) also increased DA, decreased GABA, and had a biphasic effect on Glu in the NAc similar to that observed in the NAc after carb administration. When the cytochrome P450 inhibitor N-benzylimidazole (NBI) (20 mg/kg i p) was administered before DSF dosing, no carb could be detected in the NAc and plasma and also no changes in NAc DA, GABA, and GLu occurred. Changes in these neurotransmitters occurred only if carb was formed from DSF. When NBI was administered prior to dosing with carb, the increase in DA, decrease in GABA, and biphasic effect on GLu was similar to that seen after dosing with carb only. The i p or i v administration of carb showed similar changes in DA, GABA, and GLu, except the time to reach Cmax for DA as well as the changes in GABA, and GLu after i p administration occurred later. The elimination half-life of carb and the area under the curve (AUC) were similar after both routes of administration. It is concluded that carb must be formed from DSF before any changes in DA, GABA, and GLu in the NAc and mPFC are observed. DSF and carb, when administered to rats, co-release DA, GABA, and GLu. Carb, once formed can cross the blood brain barrier and enter the brain. Although inhibition of liver ALDH2 is the accepted mechanism for DSF's action in treating AUDs, the concurrent changes in DA, GABA, and GLu in the NAc and mPFC after DSF administration suggest that changes in these neurotransmitters as a potential mechanism of action not only for AUDs, but also for cocaine dependence cannot be excluded. •Microdialysis study shows disulfiram effects on dopamine, GABA, and glutamate.•Disulfiram in NAC and mPFC increases dopamine, decreases GABA, and has biphasic effect on glutamate.•Disulfiram effect due to metabolite carbamathione.•If no carbamathione formed from disulfiram, no change in neurotransmitters occur.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>23891816</pmid><doi>10.1016/j.neuropharm.2013.07.007</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0028-3908
ispartof Neuropharmacology, 2013-12, Vol.75, p.95-105
issn 0028-3908
1873-7064
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4631046
source MEDLINE; Elsevier ScienceDirect Journals
subjects Adrenergic alpha-Antagonists - pharmacology
Analysis of Variance
Animals
Carbamathione
Disulfiram
Dopamine
Dopamine - metabolism
Dose-Response Relationship, Drug
GABA
gamma-Aminobutyric Acid - metabolism
Glutamate
Glutamic Acid - metabolism
Glutathione - analogs & derivatives
Glutathione - chemistry
Glutathione - metabolism
Glutathione - pharmacology
Imidazoles - pharmacology
Male
Microdialysis
Nucleus Accumbens - drug effects
Nucleus Accumbens - metabolism
Prefrontal Cortex - drug effects
Prefrontal Cortex - metabolism
Rats
Rats, Sprague-Dawley
Time Factors
title S-(N, N-diethylcarbamoyl)glutathione (carbamathione), a disulfiram metabolite and its effect on nucleus accumbens and prefrontal cortex dopamine, GABA, and glutamate: A microdialysis study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T08%3A28%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=S-(N,%20N-diethylcarbamoyl)glutathione%20(carbamathione),%20a%20disulfiram%20metabolite%20and%20its%20effect%20on%20nucleus%20accumbens%20and%20prefrontal%20cortex%20dopamine,%20GABA,%20and%20glutamate:%20A%20microdialysis%20study&rft.jtitle=Neuropharmacology&rft.au=Faiman,%20Morris%20D.&rft.date=2013-12-01&rft.volume=75&rft.spage=95&rft.epage=105&rft.pages=95-105&rft.issn=0028-3908&rft.eissn=1873-7064&rft_id=info:doi/10.1016/j.neuropharm.2013.07.007&rft_dat=%3Celsevier_pubme%3ES0028390813003249%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23891816&rft_els_id=S0028390813003249&rfr_iscdi=true